Bavarian Nordic
153.1
DKK
+0.03 %
Less than 1K followers
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+0.03%
-3.65%
-22.64%
-19.14%
-29.93%
+2.86%
+16.87%
-5.49%
+7.34%
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Read moreMarket cap
12.07B DKK
Turnover
9.33M DKK
Revenue
5.72B
EBIT %
16.44 %
P/E
12.15
Dividend yield-%
-
Financial calendar
9.5
2025
Interim report Q1'25
22.8
2025
Interim report Q2'25
14.11
2025
Interim report Q3'25
All
Research
Webcasts
Press releases
ShowingAll content types
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)
Correction: Beslutninger på den ordinære generalforsamling 2025 i Bavarian Nordic A/S
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools